The Filing Desk

Maravai LifeSciences

MRVI · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

MRVI · Last close · November 13, 2026
$7.54
Value Maravai LifeSciences yourself

Maravai LifeSciences' revenue fell 28.3% to $186 million in fiscal 2025. Its operating margin was −115.9%, down from −90.9% a year earlier. Free cash flow was −$71 million. The diluted share count rose 4.7%.

Maravai LifeSciences Holdings, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001823239-26-000011 Updated
Revenue
$186M
28.3%
Operating margin
−115.9%
25.0 pts
Net income
−$131M
 
Free cash flow
−$71M
 
Return on capital
−32.0%
4.6 pts
Market cap
$1.1B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Maravai LifeSciences does

Maravai LifeSciences supplies materials and services that drug companies and researchers use to develop drugs, vaccines and diagnostic tests. Its customers include large drug makers, young biotech firms, research organizations, universities and diagnostics companies.

It has two segments. TriLink, 64% of 2025 revenue, makes mRNA and other nucleic acids, which are the genetic building blocks of many vaccines and therapies. It sells research-grade and manufacturing-grade versions and mRNA manufacturing services. Its products include its patented CleanCap technology, which helps mRNA work properly in the body, and ModTail, which helps cells make more protein from mRNA. Cygnus, 36% of 2025 revenue, makes tests that detect leftover impurities, such as host cell proteins, in biologic drugs during manufacturing.

Maravai earns money by selling these products and services. It says some revenue comes from large-volume sales of CleanCap for vaccines, and that how long that lasts depends on factors outside its control. It competes with life science, drug and biotech companies that are much larger. It says it recently changed its organization, including its executive team and by cutting jobs, to lower costs.

Its biggest risks, as it describes them

  • Customers cutting their spending on its products and services, which makes its results swing.
  • Uncertainty about how long its high-volume CleanCap sales for commercial vaccines will last.
  • Changes in US federal government policies that could affect it and its customers.
  • Competing against much larger life science, drug and biotech companies that could make its products obsolete.
  • Defects or quality problems with its reagents, which would damage customers' confidence.
From Maravai LifeSciences's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2020 to 2022, earnings per share fell 15.9% a year and net income grew 57.3% a year, as new shares raised the share count by 783% and diluted each share's earnings. Maravai LifeSciences then lost money in fiscal 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments551632575322217
Debt incl. finance leases531527557328323
Net debt (negative means net cash)−21−105−185106
Net debt to EBITDA−0.0x−0.2x−2.1x——
Debt to equity1.7x1.0x1.3x1.0x1.5x
Interest coverage18.3x28.1x−0.7x−4.9x−8.0x
Current ratio7.9x7.7x8.0x7.5x6.6x
Quick ratio7.3x7.3x7.4x6.7x5.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Maravai LifeSciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Maravai LifeSciences says to expect

  • Full year 2026: revenueRevenue for the full year 2026 is expected to be in the range of $205.0 million to $215.0 million.
  • Full year 2026: adjusted EBITDAAdjusted EBITDA (non-GAAP) is now expected to be in the range of $33.0 million to $35.0 million, up from the prior range of $30.0 million to $32.0 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed August 6, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Maravai LifeSciences reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 94 of 92 of 9
Rule of 40−46.3%−18.9%−66.4%
Altman Z''4.372.711.29
Accruals ratio−13.0%−12.2%−8.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio rosePassFailFail
Share count didn't risePassFailFail
Gross margin roseFailFailFail
Revenue rose relative to assetsFailPassPass
F-score4 of 94 of 92 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Maravai LifeSciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Maravai LifeSciencesFY25−28.3%−115.9%−38.1%−32.0%—2
CryoportFY2512.4%−20.9%−14.2%−23.4%—4Compare
Cytek BiosciencesFY250.5%−20.0%−4.3%———Compare
Ginkgo BioworksFY25−25.1%−185.3%−105.0%———Compare
PacBioFY253.9%−346.1%−71.2%−77.1%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue143284799883289259186
Revenue growth—98.5%181.3%10.5%−67.3%−10.3%−28.3%
Gross profit7620465971414010834
Research and development491518171917
Operating income24120555574−32−236−215
Net income−489182220−119−145−131
Diluted EPS (US$)−0.032.361.561.67−0.90−1.05−0.90
Diluted shares (millions)25429258255132138144
Cash flow
Cash from operations241523695361268−58
Capital expenditure17251517663013
Free cash flow712735451961−22−71
Dividends paid0000000
Share buybacks03400000
Acquisitions00023970019
Stock-based compensation2251019354930
Balance sheet at fiscal year end
Cash and short-term investments25236551632575322217
Debt incl. finance leases—535531527557328323
Total assets—1,2711,9182,2821,4881,008771
Total liabilities—1,1161,3731,377698431398
Shareholders' equity14588316545417325212
Margins and ratios
Gross margin53.3%72.0%82.4%80.9%48.5%41.8%18.3%
Operating margin16.8%42.2%69.4%65.0%−10.9%−90.9%−115.9%
Net margin−3.1%31.3%22.8%24.9%−41.2%−55.9%−70.4%
Free cash flow margin4.9%44.6%44.3%58.8%21.0%−8.6%−38.1%
Rule of 40 (growth + FCF margin)—143.1%225.6%69.2%−46.3%−18.9%−66.4%
Return on capital——100.3%77.1%−2.0%−27.5%−32.0%
Return on equity——90.1%51.2%−24.8%−39.0%−48.6%
Return on assets——11.4%10.5%−6.3%−11.6%−14.7%
Net debt to EBITDA—2.0x−0.0x−0.2x−2.1x——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Maravai LifeSciences' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Maravai LifeSciences.